Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209915 | 0.85 | GAA (0.45) | GAAMAPTKDM4EHPGDTP53 | |
| SCHEMBL3202237 | 0.82 | KMT2A (0.34) | GAAALDH1A1MEN1KMT2A | |
| SCHEMBL3206406 | 0.81 | SMN1; SMN2 (0.38) | GAAMAPTKDM4EHPGDTP53 | |
| SCHEMBL3202367 | 0.78 | TP53 (0.32) | TP53TACR1FFAR4 | |
| Hydrochloric Acid SCHEMBL3259512 | 0.77 | TACR1 (0.30) | TACR1 | |
| SCHEMBL3259514 | 0.77 | TACR1 (0.30) | TACR1 | |
| SCHEMBL3209612 | 0.77 | GAA (0.46) | GAAMAPTHPGDTP53SMN1; SMN2 | |
| SCHEMBL3207767 | 0.76 | ADRB2 (0.35) | MAPTKDM4EHPGDALDH1A1MEN1 | |
| SCHEMBL3201081 | 0.76 | — | — | |
| SCHEMBL3203280 | 0.75 | TACR1 (0.31) | TP53TACR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732643-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7671226-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20100048933-A1 | TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | HANAOKA HIDENORI | 2010-02-25 | — | — | US | disclosed |
| EP-1426379-B1 | TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | SUMITOMO CHEMICAL CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20090054607-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | HANAOKA HIDENORI | 2009-02-26 | — | — | US | disclosed |
| US-7439379-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20040242410-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1426379-A1 | TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054607-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | C1R, C1S, AP1M1 | GAA 4642/4885MAPT 2641/4885KDM4E 4084/4885 |
| US-20100048933-A1 | TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | C1R, C1S, AP1M1 | GAA 4642/4885MAPT 2641/4885KDM4E 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.